236 related articles for article (PubMed ID: 29567478)
21. Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging.
Iwata H; Osborn EA; Ughi GJ; Murakami K; Goettsch C; Hutcheson JD; Mauskapf A; Mattson PC; Libby P; Singh SA; Matamalas J; Aikawa E; Tearney GJ; Aikawa M; Jaffer FA
J Am Heart Assoc; 2021 Oct; 10(20):e020834. PubMed ID: 34632804
[TBL] [Abstract][Full Text] [Related]
22. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
[TBL] [Abstract][Full Text] [Related]
23. A validated LC-MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma.
Kobuchi S; Shigemura A; Ito Y; Sakaeda T
Bioanalysis; 2020 May; 12(10):683-692. PubMed ID: 32489112
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
25. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
Fruchart JC
Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
[TBL] [Abstract][Full Text] [Related]
26. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
Tanaka A; Nakamura T; Sato E; Chihara A; Node K
CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
29. Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model.
Tomita Y; Ozawa N; Miwa Y; Ishida A; Ohta M; Tsubota K; Kurihara T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771164
[TBL] [Abstract][Full Text] [Related]
30. Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode.
Capelli D; Cerchia C; Montanari R; Loiodice F; Tortorella P; Laghezza A; Cervoni L; Pochetti G; Lavecchia A
Sci Rep; 2016 Oct; 6():34792. PubMed ID: 27708429
[TBL] [Abstract][Full Text] [Related]
31. A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms.
Kawanishi H; Ohashi K; Ogawa H; Otaka N; Takikawa T; Fang L; Ozaki Y; Takefuji M; Murohara T; Ouchi N
PLoS One; 2020; 15(6):e0235362. PubMed ID: 32584895
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys.
Ogawa SI; Tsunenari Y; Kawai H; Yamazaki H
Biopharm Drug Dispos; 2019 Jan; 40(1):12-17. PubMed ID: 30517973
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
[TBL] [Abstract][Full Text] [Related]
34. Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease.
Tanaka N; Mukaiyama K; Morikawa A; Kawakami S; Ichise Y; Kimura T; Horiuchi A
Clin J Gastroenterol; 2021 Jun; 14(3):846-851. PubMed ID: 33751406
[TBL] [Abstract][Full Text] [Related]
35. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Sairyo M; Kobayashi T; Masuda D; Kanno K; Zhu Y; Okada T; Koseki M; Ohama T; Nishida M; Sakata Y; Yamashita S
J Atheroscler Thromb; 2018 Feb; 25(2):142-152. PubMed ID: 28781340
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
[TBL] [Abstract][Full Text] [Related]
37. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.
Fruchart JC
Cardiovasc Diabetol; 2013 May; 12():82. PubMed ID: 23721199
[TBL] [Abstract][Full Text] [Related]
38. Predicting the effects of per- and polyfluoroalkyl substance mixtures on peroxisome proliferator-activated receptor alpha activity in vitro.
Nielsen G; Heiger-Bernays WJ; Schlezinger JJ; Webster TF
Toxicology; 2022 Jan; 465():153024. PubMed ID: 34743024
[TBL] [Abstract][Full Text] [Related]
39. A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor α agonists.
Patil R; Mohanty B; Liu B; Chandrashekaran IR; Headey SJ; Williams ML; Clements CS; Ilyichova O; Doak BC; Genissel P; Weaver RJ; Vuillard L; Halls ML; Porter CJH; Scanlon MJ
J Biol Chem; 2019 Mar; 294(10):3720-3734. PubMed ID: 30598509
[TBL] [Abstract][Full Text] [Related]
40. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
